Comparison of Effectiveness and Safety of Add-on Therapy of Saroglitazar and Fenofibrate with Metformin in Indian Patients with Diabetic Dyslipidaemia [PDF]
Journal of Clinical and Diagnostic Research, 2016 Introduction: Diabetic dyslipidaemia poses a therapeutic challenge. New therapies have emerged in this patient subgroup to enhance outcome and improve compliance.
Arijit Ghosh +4 more
doaj +1 more source
Emerging Role of Nuclear Receptors for the Treatment of NAFLD and NASH
Metabolites, 2022 Non-alcoholic fatty liver (NAFLD) over the past years has become a metabolic pandemic linked to a collection of metabolic diseases. The nuclear receptors ERRs, REV-ERBs, RORs, FXR, PPARs, and LXR are master regulators of metabolism and liver physiology ...
Ryan D. Welch +8 more
doaj +1 more source
Journal of International Medical Research, 2023 Objective To undertake a network meta-analysis to compare the relative efficacy of a dual peroxisome proliferator-activated receptor (PPAR)α and PPARγ agonist, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and metformin in patients with non ...
Zhuo-Ya Zhang +5 more
doaj +1 more source
To evaluate the safety and efficacy of saroglitazar among pre-diabetes and dyslipidemia
International journal of health sciences, 2022 Patients with prediabetes are not only at increased risk of progression to type 2 diabetes, but they are also at high risk of developing cardiovascular (CV) risk compared to normoglycemic people. Further, prediabetes is also often associated with abnormal lipid levels (dyslipidemia). We therefore aimed to evaluate the effect of saroglitazar in patients
Pravin G. Dhone +3 more
openaire +1 more source
From Crisis to Diagnosis: A Case of Hypertriglyceridemic Pancreatitis as the First Clinical Presentation of Type 1 Diabetes [PDF]
Journal of Clinical and Diagnostic ResearchAcute Pancreatitis (AP) is a prevalent and rapidly progressive inflammatory disorder of the pancreas, often presenting with abdominal pain and elevated serum pancreatic enzymes.
Subashini Vadivel +3 more
doaj +1 more source
PPAR agonists for the treatment of primary biliary cholangitis: Old and new tales
Journal of Translational Autoimmunity, 2023 Introduction: Primary biliary cholangitis (PBC) is an autoimmune liver disease involving the small intrahepatic bile ducts; when untreated or undertreated, it may evolve to liver fibrosis and cirrhosis. Ursodeoxycholic Acid (UDCA) is the standard of care
Francesca Colapietro +2 more
doaj +1 more source
Diabetic Dyslipidemia - Role of Saroglitazar
Medicinal Chemistry, 2014 ‘Diabetic dyslipidemia’ (combination of raised triglyceride levels, raised small-dense Low-density lipoprotein particles and low high-density lipoprotein cholesterol levels) is the most prominent risk factor of atherosclerosis and cardiovascular disease.
openaire +1 more source
Fatty liver - Current and future treatment: A narrative review
Apollo Medicine, 2021 A holistic approach is required for managing patients with nonalcoholic fatty liver disease (NAFLD). Lifestyle interventions and medical management of metabolic risk factors currently form the cornerstone of NAFLD management.
Arka De, Ajay Duseja
doaj +1 more source
Role of Glitazars in atherogenic dyslipidemia and diabetes: Two birds with one stone?
Indian Journal of Endocrinology and Metabolism, 2014 A triad of high triglycerides, low high-density lipoprotein (HDL) cholesterol, and elevated small dense low-density lipoprotein particles occurring in a patient with type 2 diabetes is referred to atherogenic diabetic dyslipidemia (ADD).
Srinivasa P Munigoti, C V Harinarayan
doaj +1 more source
Suppression of TGF-β/Smad3 signaling pathway by Capparis spinosa and quercetin in a rat model of nonalcoholic steatohepatitis [PDF]
Iranian Journal of Basic Medical SciencesObjective(s): Liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), pose significant global public health challenges.
Reza Afarin +4 more
doaj +1 more source